Search results for:
Ondine’s C$19m fundraise enables Q4 2024 start of Phase 3 US trial
Updated November 15, 2025 to reflect further funds raised. Canadian life sciences company Ondine Biomedical announces that it is accelerating its final preparations for a Q4 2024 start to its key pivotal US Phase 3 trial following its recent successful raise of Cdn $19.2 million (c. £10.8 million). Alongside [...]
Ondine continues commercial growth
Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has made significant progress with the commercial roll-out of its novel nasal decolonization technology, Steriwave®, in both Canada and the UK. Steriwave is a simple 5-minute procedure that reduces healthcare-associated infections [...]
King’s College Hospital to run Steriwave pilot
Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, confirms that King’s College Hospital (KCH) will be running a pilot of its Steriwave® light-activated antimicrobial technology. KCH, a globally recognized leader in healthcare innovation and one of London’s largest teaching hospitals, will be [...]
Steriwave receives UAE Regulatory Approval
Ondine receives regulatory approval for Steriwave light-activated antimicrobial technology in the United Arab Emirates Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has received regulatory approval to market Steriwave® nasal decolonization to reduce healthcare-associated infections (HAIs) in patients undergoing [...]
Collaboration advances Steriwave for ICU Market
Royal Columbian Hospital Foundation’s Advancing Innovation in Medicine (AIM) division supports Steriwave ICU use with clinical trials at Royal Columbian Hospital Treatment of patients in intensive care units (ICUs) would significantly expand Ondine’s market opportunity. Infection prevention is a top priority in ICUs as they face higher infection [...]
Ondine secures C$5 million financing
All references to C$ in this announcement are to Canadian Dollars. This Announcement uses a C$:£ exchange rate of 1 : 0.555041 as at 16:30 (GMT) on 23 September 2024. Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that it has agreed [...]
Mölnlycke® and Ondine Join Forces Against HAIs
Mölnlycke Health Care partners with Ondine for Steriwave distribution collaboration in the key markets of the UK, Europe and the Middle East Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, and Mölnlycke Health Care (Gothenburg Sweden), a world-leading MedTech company that specializes in innovative [...]
Steriwave in all British Columbia Health Authorities
Vancouver, British Columbia, Canada - August 23, 2024 Ondine Biomedical Inc. (LON: OBI), a leading provider of light-activated antimicrobial technology to prevent and treat hospital infections, is pleased to announce that Steriwave® nasal decolonization is now being used in all five of British Columbia's health [...]
Leeds Teaching Hospitals NHS Trust to use Steriwave
Vancouver, British Columbia, Canada - August 6, 2024 Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, and Iskus Health announce that Leeds Teaching Hospitals NHS Trust will begin using its Steriwave® nasal decolonization technology later this month. Leeds Teaching [...]
Ondine CMO interviewed in European Biopharmaceutical Review
Ondine Biomedical's Chief Medical Officer, Simon Sinclair, has been interviewed for the Summer edition of European Biopharmaceutical Review about the risks of AMR and rising rates of hospital infections. Read the full interview here: Antimicrobial resistance and healthcare-associated infections: the current landscape and the future.
For Media Information
Simon Vane Percy
Amanda Bernard
